Publications by the researcher in collaboration with JESÚS FERNANDO SAN MIGUEL IZQUIERDO (242)

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  2. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  3. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

    Blood, Vol. 141, Núm. 3, pp. 219-230

  4. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

    Leukemia, Vol. 37, Núm. 7, pp. 1521-1529

  5. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

    Frontiers in Oncology, Vol. 13

  6. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  7. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

    Blood, Vol. 142, Núm. 18, pp. 1518-1528

  8. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311

  9. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1383-1392

  10. Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

    HemaSphere

  11. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269

  12. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

    Haematologica, Vol. 108, Núm. 10, pp. 2753-2763

2022

  1. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research

  2. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  3. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161